The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1180
April 12, 2004
View Complete Issue         Table of Contents 2019 
Pemetrexed (Alimta) for Mesothelioma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Pemetrexed (Alimta) for Mesothelioma
April 12, 2004 (Issue: 1180)
The combination of pemetrexed (Alimta - Lilly) and cisplatin is the first chemotherapy regimen approved by the FDA for treatment of malignant pleural mesothelioma. This uncommon malignancy, which has been linked to asbestos exposure, was previously...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Pemetrexed (Alimta) for Mesothelioma
Article code: 1180b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.